Supplementary Materialsmmc1. malignancy, perspective on telehealth steps as a reaction to the current COVID-19 pandemic, and long-term acceptance were used as results. Wilcoxon matched-pair authorized rank test, chi-square test, and Mann-Whitney U test were performed. Results and limitations Of 101 individuals, 92 solved the questionnaire, with 71 (77.2%) responding virtually by e-mail or phone call. Panic of malignancy (6/10, interquartile range [IQR] 3C8) superseded that of COVID-19 (four/10, IQR 2C5.25, test and chi square test with Prism 8 software (GraphPad Software, San Diego, CA, USA). 3.?Results Out of 101 individuals currently under therapy or monitoring in the uro-oncology unit, 92 (91.1%) responded to the survey via e-mail, phone call, or in person (88.7% [=37) with immune checkpoint inhibitors ( em n /em ?=?45), chemotherapy ( em n /em ?=?34), androgen deprivation therapy ( em n /em ?=?5), tyrosine kinase inhibitors ( em n /em ?=?5), or other therapies ( em n /em ?=?3). Demographic characteristics are enlisted in Table 1 . Table 1 Patient characteristics thead th align=”remaining” rowspan=”1″ colspan=”1″ /th th colspan=”2″ align=”center” rowspan=”1″ em n /em ?=?92 /th /thead Age?Median69?Range33C88 em n /em %Sex?Male7480.4?Woman1819.6Cancer?Prostate3032.6?Bladder3740.2?Kidney2527.2Therapy?Immunotherapy4548.9?Chemotherapy3437.0?Tyrosine kinase inhibitor therapy55.4?Androgen deprivation therapy55.4?Additional33.3Chronic underlying condition?Hypertension5357.6?Cardiac disease2729.3?Diabetes1819.6?Renal disease1213.0?Obesity1112.0?Pulmonary disease66.5?Jeopardized immune system33.3 Open in a separate window 3.1. Panic of COVID-19 and malignancy Overall panic from COVID-19 is at a median of 4 (interquartile range [IQR] 2C5.25), while median anxiety of the current cancer situation is at a median of 6 (IQR 3C8; em p /em ? ?0.001). Belief of panic allows the recognition of four categories of individuals: vulnerable and RNASEH2B frightened (37%), malignancy dominated (28.3%), COVID-19 dominated (7.6%), and fearless fighters (27.2%; Fig. 2A). Of the individuals, 56.5% are more anxious about their malignant disease than about COVID-19, whereas 26.1% are more anxious about COVID-19 ( em p /em ? ?0.001; Fig. 2B). Open in a separate windows Fig. 2 Panic of COVID-19 and malignancy. (A) Current belief of panic is rated from 0 (no panic) to 10 (intense panic). Individuals with panic levels for COVID-19 and malignancy of 5 were classified as fearless fighters and those with panic levels of at least 5 as vulnerable and scared. Individuals with panic level of either COVID-19 or malignancy of at least 5 were classified as COVID-19 dominated or malignancy dominated. (B) Panic 1001645-58-4 was ranked accordingly and individuals with higher levels of panic of their malignancy were classified as more anxious about malignancy, whereas those with higher levels of panic of COVID-19 were classified as more anxious of COVID-19. Individuals with equally high levels were ranked as equally anxious. COVID-19?=?coronavirus disease-19. 3.2. Susceptibility to COVID-19 and its impact on therapy Of the patients, 88.0% perceive preparedness of the German health care system to be superior to international comparators (Supplementary Fig. 1). Our respondents estimated their risk of infection to be lower (26.4%), equal (39.6%), or higher (34.1%) than the general populace. There is no significant difference between patients on chemotherapy or immunotherapy (Fig. 3A). Of the patients, 25.0% suspect that COVID-19 will have a significant impact on their cancer treatment (Fig. 3B): the majority of the 1001645-58-4 patients value continuation of their therapy higher than the prevention steps against COVID-19 and 77.2% of them are unwilling to postpone a staging examination (Fig. 3B). Of the cohort, 44.6% is afraid of progression and does not want to interrupt or delay cancer treatment due to 1001645-58-4 the outbreak. Patients on chemotherapy are significantly less willing to interrupt or delay their therapy (61.8%) than patients on immunotherapy (33.3%, em p /em ?=?0.021; Supplementary Fig. 2). Open in a separate window Fig. 3 Susceptibility to cancer and impact on therapy. (A) Risk for contamination compared with the overall populace was assessed as lower, equal, or higher by patients. (B) Patients preference is ranked as low (0C3), 1001645-58-4 medium (4C6), or high (7C10) depending on their answers for the three respective questions. Percentages may not total 100 because of rounding. COVID-19?=?coronavirus disease-19. 3.3. Perspective on telehealth efforts implemented.